Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage  E. Ruppé, C. Burdet, N. Grall, V. de Lastours,

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000–2012  M. Tvede,
Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods  A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède,
J.-C. Lagier  Clinical Microbiology and Infection 
L. Boyanova  Clinical Microbiology and Infection 
The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection  R. Singh, M. Nieuwdorp, I.J.M.
Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors  S. Amit, H. Mishali, T. Kotlovsky,
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
Gut bacterial microbiota and obesity
I.J. Schalk  Clinical Microbiology and Infection 
Changes in the intestinal microbiota from adulthood through to old age
Time-trends for Gram-negative and multidrug-resistant Gram-positive bacteria associated with nosocomial infections in German intensive care units between.
Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources  N. Singh,
Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis  J.
Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis  T. Steinmetz, N.
M. R. Haverkate, T. N. Platteel, A. C. Fluit, J. W. Cohen Stuart, M. A
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Migrant health—a cause for concern?
Evolution of extended-spectrum β-lactamases by mutation
Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics  Y.H. van Beurden, S. Nezami,
Defining an extended-spectrum β-lactamase
Evaluation of VITEK 2 for analysis of Enterobacteriaceae using the Advanced Expert System (AES) versus interpretive susceptibility guidelines used at.
Refugee crisis and re-emergence of forgotten infections in Europe
Controversies in guidelines for the control of multidrug-resistant Gram-negative bacteria in EU countries  J.A. Otter, N.T. Mutters, E. Tacconelli, A.
P. Nordmann, L. Poirel  Clinical Microbiology and Infection 
A.E. Muller, U. Theuretzbacher, J.W. Mouton 
Extended-spectrum β-lactamase/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans?  J.-Y. Madec, M. Haenni, P. Nordmann,
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012  V.
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum.
Impact of antibiotic restrictions: the pharmaceutical perspective
Vector control: a cornerstone in the malaria elimination campaign
Do we need new antibiotics?
J.P. Donnelly, B.E. De Pauw  Clinical Microbiology and Infection 
Quantamatrix Multiplexed Assay Platform system for direct detection of bacteria and antibiotic resistance determinants in positive blood culture bottles 
Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre.
CMI editorial report 2011 Clinical Microbiology and Infection
Control of infections due to extended-spectrum β-lactamase-producing organisms in hospitals and the community  R.E. Warren, G. Harvey, R. Carr, D. Ward,
The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study  E. Manea, J. Sojo-Dorado, R.E. Jipa, S.N.
In vitro selection of antibiotic resistance in Pseudomonas aeruginosa
Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital  L. Gibold, F. Robin, R.-N.
Levofloxacin in the treatment of ventilator-associated pneumonia
R. Bitterman, M. Paul, D. Polak, Y. Geffen 
M. Aires-de-Sousa  Clinical Microbiology and Infection 
Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case–control study  M.
Laboratory diagnosis of Clostridium difficile disease
Systematic review of antibiotic consumption in acute care hospitals
Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases  L. Romero, L. López,
Cessation of screening for intestinal carriage of extended-spectrum β-lactamase- producing Enterobacteriaceae in a low-endemicity intensive care unit with.
S. M. Bartsch, J. A. McKinnell, L. E. Mueller, L. G. Miller, S. K
Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit  S. Nseir, C. Blazejewski, R. Lubret,
Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013  U. Fedeli, E. Schievano,
R. Cantón, A. Novais, A. Valverde, E. Machado, L. Peixe, F. Baquero, T
Clinical Microbiology and Infection
Microbiologic factors affecting Clostridium difficile recurrence
Can pharmacokinetic–pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?  P. Courvalin  Clinical Microbiology and.
E. Tacconelli  Clinical Microbiology and Infection 
Virology: a scientific discipline facing new challenges
New oral cephalosporins in pediatric community-acquired infections
Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci  V. Sakka, S. Tsiodras, L. Galani, A. Antoniadou,
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Typing of Clostridium difficile
Great oaks from little acorns grow—21 years of CMI
Impact of antibiotic restrictions: the patient's perspective
Impact of a targeted isolation strategy at intensive-care-unit-admission on intensive- care-unit-acquired infection related to multidrug-resistant bacteria:
CMI readers' survey Clinical Microbiology and Infection
The future of diagnostic bacteriology
Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre.
Presentation transcript:

Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage  E. Ruppé, C. Burdet, N. Grall, V. de Lastours, F.-X. Lescure, A. Andremont, L. Armand-Lefèvre  Clinical Microbiology and Infection  Volume 24, Issue 1, Pages 3-5 (January 2018) DOI: 10.1016/j.cmi.2017.09.017 Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Proposition for the assessment of the impact of antibiotics on the intestinal microbiota. MDRB, multidrug-resistant bacteria; ESBL-PE, extended-spectrum β-lactamase-producing Enterobacteriaceae; CPE, carbapenemase-producing Enterobacteriaceae; VRE, vancomycin-resistant enterococci; PK, pharmacokinetic. Here, MDRB refers to ESBL-PE, CPE, VRE and Clostridium difficile. The score reflecting the impact on the intestinal concentrations of ESBL-PE, CPE, VRE and C. difficile is calculated as the log10 of the ratio between their intestinal concentrations after and before antibiotic exposure. A positive ratio therefore means that the antibiotic promoted the growth of ESBL-PE, CPE, VRE or C. difficile. Conversely, antibiotics are expected to decrease the intestinal richness and diversity. To be consistent with the direction of the previous MDRB scores, that reflecting the impact on diversity and richness of gut microbiota was defined the other way round, i.e. by the ratio between the respective diversity indices (Shannon or Simpson) and richness before and after antibiotic exposure. Hence, the higher the score, the greater the impact of the antibiotic on the microbiota in terms of diversity and richness. The values of the scores for the antibiotics A, B and C were arbitrarily chosen for illustrative purposes. Clinical Microbiology and Infection 2018 24, 3-5DOI: (10.1016/j.cmi.2017.09.017) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions